Opaleye Management’s Iovance Biotherapeutics IOVA Stock Holding History

Opaleye Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-897,000	Closed	-$7.19M	–	49
2024 Q2	$7.19M	Hold	897,000	–	–	1.64%	19
2024 Q1	$13.3M	Hold	897,000	–	–	2.9%	8
2023 Q4	$7.29M	Buy	897,000 +287,000	+47%	+$1.5M	1.94%	15
2023 Q3	$2.78M	Buy	610,000 +189,000	+45%	+$1.23M	0.9%	30
2023 Q2	$2.96M	Hold	421,000	–	–	0.71%	33
2023 Q1	$2.57M	Buy	+421,000	New	+$2.9M	0.77%	33
2018 Q4	–	Sell	-325,000	Closed	-$3.66M	–	51
2018 Q3	$3.66M	Buy	+325,000	New	+$4.61M	0.93%	31
2017 Q2	–	Sell	-230,000	Closed	-$1.71M	–	44
2017 Q1	$1.71M	Sell	230,000 -70,000	-23%	-$513K	0.85%	32
2016 Q4	$2.08M	Buy	300,000 +20,000	+7%	+$138K	1.23%	25
2016 Q3	$2.3M	Buy	280,000 +20,000	+8%	+$169K	1.21%	31
2016 Q2	$2.11M	Buy	+260,000	New	+$1.63M	1.41%	26
2015 Q2	–	Sell	-200,000	Closed	-$2.42M	–	48
2015 Q1	$2.42M	Buy	+200,000	New	+$2.25M	1.12%	28

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Opaleye Management's IOVA Position: Q3 2024 in Review

Opaleye Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 897,000 shares — an estimated $7.19M sold.

Opaleye Management first reported a position in IOVA in Q1 2015 and held it in 12 quarters. The position peaked at $13.3M in Q1 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

Opaleye Management reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Opaleye Management sold 897,000 Iovance Biotherapeutics shares in Q3 2024, an estimated $7.19M.
Opaleye Management first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 12 quarters.
Opaleye Management's Iovance Biotherapeutics position peaked at $13.3M in Q1 2024.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.